Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT02453282. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC
Study identification
- NCT ID
- NCT02453282
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,118 participants
Conditions and interventions
Conditions
Interventions
- MEDI4736 (Durvalumab) Biological
- MEDI4736 (Durvalumab)+Tremelimumab Biological
- Paclitaxel + Carboplatin Drug
- Gemcitabine + Cisplatin Drug
- Gemcitabine + Carboplatin Drug
- Pemetrexed + Cisplatin Drug
- Pemetrexed + Carboplatin Drug
- Tremelimumab Biological
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 21, 2015 (Actual)
- Primary completion
- Oct 4, 2018 (Actual)
- Completion
- Dec 31, 2026 (Estimated)
- Last update posted
- Aug 6, 2026
2015 – 2026
United States locations
- U.S. sites
- 35
- U.S. states
- 18
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Scottsdale | Arizona | 85259 | — |
| Research Site | Tucson | Arizona | 85715 | — |
| Research Site | Yuma | Arizona | 85364 | — |
| Research Site | Bakersfield | California | 93309 | — |
| Research Site | Fullerton | California | 92835 | — |
| Research Site | La Jolla | California | 92093 | — |
| Research Site | Los Angeles | California | 90024 | — |
| Research Site | Los Angeles | California | 90073 | — |
| Research Site | Redondo Beach | California | 90277 | — |
| Research Site | Sacramento | California | 95817 | — |
| Research Site | San Luis Obispo | California | 93401 | — |
| Research Site | Santa Maria | California | 93454 | — |
| Research Site | West Hollywood | California | 90048 | — |
| Research Site | New Haven | Connecticut | 06519 | — |
| Research Site | Jacksonville | Florida | 32256 | — |
| Research Site | Pembroke Pines | Florida | 33028 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Athens | Georgia | 30607 | — |
| Research Site | Honolulu | Hawaii | 96819 | — |
| Research Site | Baltimore | Maryland | 21231 | — |
| Research Site | Minneapolis | Minnesota | 55435 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Omaha | Nebraska | 68198 | — |
| Research Site | Summit | New Jersey | 07901 | — |
| Research Site | Mineola | New York | 11501 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | New York | New York | 10021 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | Charlotte | North Carolina | 28204 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | North Charleston | South Carolina | 29406 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Nashville | Tennessee | 37232 | — |
| Research Site | Richmond | Virginia | 23298 | — |
| Research Site | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 161 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02453282, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 6, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02453282 live on ClinicalTrials.gov.